Go Deep
MBX Biosciences, Inc.
MBX Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,830 | -20.7 | 5.76 | 0.01 | 4,666.45 |
| Oct 2026 | 17,853 | -20.6 | 5.74 | 0.01 | 4,635.34 |
| Oct 2026 | 17,611 | -21.5 | 5.96 | 0.01 | 4,815.47 |
| Oct 2026 | 17,752 | -20.9 | 5.83 | 0.01 | 4,698.81 |
| Oct 2026 | 17,384 | -22.1 | 6.17 | 0.01 | 4,975.96 |
| Oct 2026 | 17,256 | -22.6 | 6.29 | 0.01 | 5,072.68 |
| Oct 2026 | 17,201 | -22.8 | 6.34 | 0.01 | 5,100.82 |
| Oct 2026 | 17,645 | -21.3 | 5.93 | 0.01 | 4,762.96 |
| Oct 2026 | 17,896 | -20.5 | 5.70 | 0.01 | 4,596.94 |
MBX Biosciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -37,095,000.0 | -23,517,000.0 | -22,062,000.0 | -21,618,000.0 |
| EPS | -0.8 | -0.5 | -0.5 | -0.6 |
MBX Biosciences, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -86,971,000.0 | -61,922,000.0 | -32,563,000.0 | -26,135,000.0 |
| EPS | -2.4 | -5.8 | -1.0 | -0.8 |
MBX Biosciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 385,144,000.0 | 268,535,000.0 | 84,180,000.0 | 45,095,000.0 |
| Total Liabilities | 15,921,000.0 | 11,093,000.0 | 156,648,000.0 | 87,700,000.0 |
| Total Equity | 369,223,000.0 | 257,442,000.0 | -72,468,000.0 | -42,605,000.0 |
Owes vs Owns
MBX Biosciences, Inc. owed $0.06 for every $1 it owned in Jun 2026, down from $1.94 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.06× | 0.04× | 0.04× | 1.86× | 1.94× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
MBX Biosciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 97.0%Receivables 0.6%Fixed assets (tangible) 0.8%Other assets 1.6%
How it's funded — Dec 2025
Payables 0.8%Other liabilities 3.2%Shareholders' equity 95.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 373.7 | 262.1 | 80.7 | 42.5 |
| Receivables | 2.1 | 0.7 | 0.2 | 0.1 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 3.2 | 1.2 | 0.7 | 0.8 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 6.1 | 4.5 | 2.6 | 1.6 |
| Liabilities & equity | ||||
| Short-term debt | 0.2 | 0.2 | 0.2 | 0.1 |
| Long-term debt | 0.4 | 0.0 | 0.2 | 0.3 |
| Payables | 3.0 | 5.3 | 1.4 | 1.0 |
| Other liabilities | 12.3 | 5.6 | 154.9 | 86.3 |
| Shareholders' equity | 369.2 | 257.4 | -72.5 | -42.6 |
| Net tangible assets | 369.2 | 257.4 | -72.5 | -42.6 |
MBX Biosciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -79,949,000.0 | -54,681,000.0 | -31,978,000.0 | -23,122,000.0 |
| Investing Activities | -83,705,000.0 | -160,595,000.0 | -30,927,000.0 | -11,411,000.0 |
| Financing Activities | 189,592,000.0 | 234,104,000.0 | 69,218,000.0 | 46,063,000.0 |